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Transcriptional co-activators, co-repressors and chromatin remodeling machines are essential ele-
ments in the transcriptional programs directed by the master adipogenic transcription factor
PPARc. Many of these components have orthologs in other organisms, where they play roles in
development and pattern formation, suggesting new links between cell fate decision-making and
adipogenesis. This review focuses on bromodomain-containing protein complexes recently shown
to play a critical role in adipogenesis. Deeper understanding of these pathways is likely to have
major impact on treatment of obesity-associated diseases, including metabolic syndrome, cardio-
vascular disease and Type 2 diabetes. The research effort is urgent because the obesity epidemic is
serious; the medical community is ill prepared to cope with the anticipated excess morbidity and
mortality associated with diet-induced obesity.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. A newly described gene that inﬂuences obesity
Worldwide, 1.7 billion people are classiﬁed as overweight [1].
Excess consumption of calories leads to human obesity, which is
one of the major health crises of this century. The World Health
Organization estimates that 171 million people worldwide have
diabetes, due primarily to obesity. This ﬁgure is expected to at least
double by 2030. The US Centers for Disease Control reports that six
US states currently have a prevalence of obesity ofP30% and only
one state (Colorado) has a prevalence of obesity of <20%. Obesity ischemical Societies. Published by E
; BAT, brown adipose tissue;
one morphogenetic proteins;
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rs contributed equally to thischaracterized by dysregulated metabolism, dyslipidemia, insulin
resistance, metabolic syndrome, non-alcoholic fatty liver disease,
hyperglycemia, hypertension, some forms of cancer and increased
risk for development of Type 2 diabetes (T2D) and its co-morbidi-
ties, the most serious of which is cardiovascular disease (CVD).
About 90% of T2D is attributable to excess weight [2]. Unless re-
versed, the deepening problem of obesity predicts an epidemic of
these co-morbidities that will strain or break many health care
delivery systems. Thus, obesity poses a formidable challenge of
overarching importance for public health. However, the obesogenic
genes, transcriptional processes and chromatin regulation that
control weight gain remain incompletely understood.
The in vivo mechanisms that regulate adipogenic transcription
are crucial for cell fate decisions, the formation of adipose tissue
from progenitors and the response of adipocytes to over-nutrition.
Recent work showing that mice with reduced whole-body expres-
sion of the ubiquitously expressed, dual bromodomain protein
Brd2 (‘Bromodomain-containing 2’) have dramatically expanded
adipose tissue [3], has refocused attention on the role of bromod-
omain-containing transcriptional co-activators/co-repressors in
adipogenesis. Speciﬁcally, Brd2 hypomorphic mice, which harbor
a lacZ disruption of the gene that encodes this transcriptional co-
activator/co-repressor, showed severe adipogenesis and obesity.
These ‘brd2 lo’ animals gained fat on an ad libitum diet of regular
rodent chow to weights approaching 100 g by 12 months of age.
At all ages, brd2 lomice accumulate about twice the fat of matchedlsevier B.V. All rights reserved.
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mice on chow diet were signiﬁcantly larger than age-matched
wild-type controls on chow diet: 62.9% of brd2 lo adipocytes were
larger than 10000 lm2, compared to only 1.1% of wild-type adipo-
cytes (P < 0.001) [3]. Interestingly, all adipose depots were healthy;
severe obesity was observed without concomitant insulin resis-
tance. Until this report, Brd2 function had not been linked to obes-
ity or glucose homeostasis.
Signiﬁcantly, shRNA knockdown of Brd2 in 3T3-L1 pre-adipo-
cytes strongly promotes adipogenic differentiation. Pre-adipocytes
with Brd2 stably knocked down show about 50% more Oil Red O
staining upon insulin/dexamethasone/isobutylmethylxanthine dif-
ferentiation than control adipocytes. Brd2 and PPARc are each
detectable by co-immunoprecipitation of the other, and shRNA
knockdown in vitro of Brd2 in 3T3-L1 cells approximately doubles
the signal from a PPAR-responsive element (PPRE)-regulated tran-
scriptional reporter. Taken together, these results suggest a mech-
anism that works through alleviated Brd2 co-repression of PPARc-
directed transcription of adipogenic genes [3]. Previous work has
identiﬁed histone modiﬁcation enzymes and nucleosome remodel-
ing proteins associated with Brd2-containing multiprotein com-
plexes [4,5]. These new results offer an opportunity to revisit
what is known about the role of chromatin in adipogenic transcrip-
tion and to develop hypotheses that will channel effort into a dee-
per excavation of the relevant mechanisms.
2. The bromodomain and extraterminal domain (BET) family of
regulators
The metazoic members of the Brd2 family, the best known sub-
group of BET proteins, possess dual, mutually-related bromodo-
mains in the amino-terminal region of the protein that bind to
acetylated chromatin, and protein–protein interaction domains
for association with transcription machinery in the carboxyl-ter-
minal region. The bromodomains account for the reported co-
localization with chromosomes of this protein family (Fig. 1). Spe-
ciﬁcally, the bromodomains bind to acetylated lysine 12 of histone
H4 in nucleosomal promoters [6], a chromatin-binding function
ﬁrst illustrated for the single-bromodomain histone acetyltransfer-
ase (HAT) Gcn5 [7] and P/CAF (a p300/CREB binding protein-asso-
ciated factor) [8]. Structural requirements for chromatin
interaction have been established in detail for Brd2 [5,6,9,10]. Sim-
ilar interactions have been reported for other dual bromodomain
proteins such as Brd3 [11,12], Brd4 [13–15], Brd6 [Brdt; 16], the
basal transcription factor TAFII250 [17,18] and Brd2 gene ortho-
logs: Saccharomyces BDFI [19–21], Arabidopsis GTE4 [22], Drosophila
female sterile (1) homeotic (fs(1)h) [23–25], Caenorhabditis bet-1
[26], and Danio and Xenopus brd4 [27]. Dual bromodomain proteins
thereby couple histone acetylation to transcription in a wide vari-
ety of organisms and transcriptional contexts.Fig. 1. Major forms of BET proteins. The structure of human Brd2 is compared to human B
100 amino acids in length and are highly homologous to each other. They are separated by
sequence (NLS), an ATP binding/kinase domain (ATP), a multiprotein complex association
Brd2 BD1 is located between amino acid positions 75 and 175, and BD2 is located betwee
that lacks association motifs. fs(1)h possesses a number of insertions, also of unknown
alternative start sites and splice sites, but tend to cluster into one of two subtypes: either
or a long form with an unstructured carboxyl terminal tail (Brd4). [See Ref. [66] for moThis highly conserved family of transcriptional co-regulators is
primarily known for function in cell fate during development, in
cancer and the cell cycle. Dual bromodomain proteins have crucial
functions in pattern formation in Drosophila [28–32] and mice
[13,33,34]. Mutation of fs(1)h causes severe defects in differentia-
tion and cell fate; fs(1)hnull is lethal [23,29,35]. The fs(1)h locus is
an upstream activator of trithorax in Drosophila [30,36], an impor-
tant, homeotic control gene that positively regulates Hox-con-
trolled differentiation in mice, countering repression by the
Polycomb group (PcG) proteins. Disruption of human BRD4
through t(15;19) chromosomal translocation generates aggressive
midline carcinomas [37; reviewed in 38]. Brd2 and Brd4 control
cell cycle in mice [13,39,40] and in cultured cells [5,41]. In the
mouse, Brd4 is necessary for the G2-to-M transition of the cell
cycle, and brd4(+/) mice show severe defects in differentiation
and organogenesis. In mice, brd4null is lethal [13,42,43]. The TA-
FII250 subunit of the TFIID basal transcription factor complex
[44] is also crucial for cell cycle control through its regulation of cy-
clin A, which is a critical driver of S phase [45]. Brd2 transduces
mitogenic signals [46,47], leading to increased proliferation [48].
Forced expression of Brd2 transcriptionally co-activates cyclin A,
causing earlier S phase entry during cell cycle progression [5].
Brd2 constitutive expression in B cell progenitors causes a B cell
malignancy in mouse models [40] that is most similar to human
diffuse large B cell lymphoma [49,50]. Thus, the dual bromodomain
proteins exert non-redundant, chromatin-based activities that are
essential for growth, development, differentiation and cell cycle
progression.
These proteins use a structural component, the bromodomain,
to bring transcriptional functions to chromatin that has already
been identiﬁed for transcriptional regulation through histone
hyperacetylation or sequence-speciﬁc DNA-binding transcription
factors. Virtually all of the nuclear HATs contain bromodomains
[51,52], but not all bromodomain proteins are HATs. Instead, the
enzymatic activities (HAT or ATP-dependent chromatin remode-
lase) are either encoded within the same polypeptide chain or
are recruited to a multiprotein complex, including bromodomain
proteins resident at the promoter, thereby coupling structure to
function. Chromosomal translocation can decouple this system,
targeting HAT activity to the wrong promoter [53], a genetic abnor-
mality frequently associated with cancer [38,54–57].
3. The bromodomain motif
In 1992, the bromodomain was ﬁrst noticed as a primary amino
acid sequence present in certain proteins that have chromatin or
transcription functions [58]. Many bromodomain-containing pro-
teins are found in transcription complexes [51,52], where they per-
form scaffolding functions [59]. The bromodomain takes its name
from Drosophila brahma (BRM), an important chromatin-modify-rd4 and the long form of Drosophila fs(1)h. Both Brd2 bromodomains (BD) are about
a basic domain (++), followed by an acidic domain (), a short nuclear localization
domain (assoc) 164 amino acids in length and an acidic polyserine (SEED) domain.
n 350 and 450. Brd4 possesses a long carboxyl-terminal region of unknown function
function. The two largest insertions are shown. Mammalian BET proteins exhibit
a short form with dual bromodomains and an association domain (Brd2, Brd3, Brd6),
re detailed discussion.]
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in a prescient 1994 paper of Randazzo and colleagues [61], who
noted that brahma (Snf2a, SMARCA2) likely assists trithorax to
overcome Polycomb repression of chromatin. Given the crucial role
played by the human homolog of trithorax (MLL) in mixed lineage
leukemias derived from 11q23 chromosomal translocations
[62,63], they speculated that the brahma-related bromodomain
protein BRG1 (Snf2b, SMARCA4), which is an essential catalytic
component of the SWI/SNF complex (discussed in detail below),
would be implicated in mammalian malignancy, as later work ver-
iﬁed [64,65]. The conserved, 110 amino acid bromodomain motif
is comprised of four left-handed a helices bundled together and
connected with two segments, the so-called ZA and BC loops. The
structure was solved ﬁrst by analysis of nuclear Overhauser effects
in the P/CAF single bromodomain [8]. The ﬁeld has enjoyed a num-
ber of excellent reviews that discuss the relationship between
bromodomain protein structure and transcriptional co-activation
or co-repression function [53,66–68].4. Transcriptional co-activation and co-repression by
bromodomain proteins
Bromodomain proteins that encode HAT activity, or recruit HAT
enzymes to chromatin, establish a paradigm for transcriptional co-
activation. The model also implies that a basal level of histone acet-
ylation of nucleosomes is required to catalyze the initial associa-
tion with bromodomain proteins. It is widely appreciated that
histone hyperacetylation is a mark of transcription activation of
promoter chromatin. Brd2 binds endogenous cyclin A promoter
chromatin, but mutants of Brd2 with deleted bromodomains or
carboxyl-terminal protein association domains do not transacti-
vate [5]. Functional cis-acting E2F binding sites are required for
Brd2-dependent transcriptional function on the cyclin A promoter
[48], and overexpressed retinoblastoma protein (RB), which halts
E2F-dependent cell cycle progression [69], ablates Brd2-driven
transactivation [48]. E2F1 and E2F2 are present in Brd2 multipro-
tein complexes puriﬁed from nuclear extracts [48] and Brd2 works
with E2Fs to recruit HAT activity and other epigenetic regulators,
including Mediator complex proteins, and the hSWI/SNF compo-
nent BAF155, to chromatin [4,5] thus to transactivate cyclin A. Dys-
regulation of this process leads to the classic disease of
uncontrolled proliferation: cancer [40].
Transcriptional programs that promote cellular proliferation/
cell cycle progression function in balance with programs that pro-
mote cellular differentiation/cell cycle exit. The balance between
the two lies at the heart of cell decisions to grow, specialize or un-
dergo apoptosis. Imbalances are pathogenic. For example, diverse
leukemias arise in the bone marrow through defective differentia-
tion closely coupled to abnormal proliferation [70–72]. The resul-
tant leukemic blasts are often blocked at an early stage of
differentiation, consistent with their continued active proliferation
at the expense of normal differentiation. Important and effective
therapies for certain leukemias take advantage of this transcrip-
tional switch as a rationale to treat leukemic patients with differ-
entiation-promoting agents, such as retinoic acid derivatives that
force cell cycle exit and block proliferation [73,74].
Bromodomain proteins also play important roles in transcrip-
tional co-repression, as ﬁrst identiﬁed in studies showing that
the bromodomain protein BRM contacts RB [75,76]. RB and its fam-
ily members p107 and p130 bind to E2F proteins and block their
transcription activation function to oppose cell cycle progression.
RB also recruits a histone deacetylase (HDAC), as do p107 and
p130, through contact with BRM and other proteins in the SWI/
SNF complex [77–80]. Not all SWI/SNF complexes contribute to
this repressive function, however. Indeed, recent studies indicatethat a speciﬁc variant SWI/SNF complex (the ARID1A BAF complex)
is important for repression of E2F activated cell cycle control genes,
whereas another variant (the ARID1B BAF complex) contributes to
the activation of these genes [81,82]. Until recently [3], there was
no evidence of a role for Brd2 in mammalian transcriptional co-
repression, although clues from studies of Drosophila development
identiﬁed in fs(1)h, the homolog of Brd2, transcriptional repression
functions that are essential for proper differentiation in the early
embryo [38,83].
5. The SWI/SNF complex
As discussed above, local modiﬁcation of histones on enhancers
and promoters is required to activate gene expression [84,85].
Transcription factors that bind to nucleosome-free regions of
DNA or to DNA within nucleosomes recruit enzymatic activities
that also non-covalently modify the surrounding chromatin archi-
tecture. These ATP-dependent remodeling complexes may contrib-
ute to gene regulation through a variety of mechanisms, including
movement in cis of nucleosomes away from or over regulatory ele-
ments, removal or deposition of nucleosomes in conjunction with
cellular chaperones, changes in the histone composition of nucleo-
somes, regulation of covalent histone modiﬁcations, alteration of
nucleosome structure, and/or changes in higher order chromatin
folding. While these models mostly derive from in vitro biochem-
ical studies, examples of many of these effects in gene regulation
are beginning to accumulate [86].
The SWI/SNF complex offers an important example of an evolu-
tionarily conserved, bromodomain-containing, ATP-dependent
chromatin remodeling machine, with roles in both transcriptional
activation and repression [65,87,88]. Mammalian SWI/SNF com-
prises a 2 MDa complex that possess the essential, catalytic pro-
teins brahma-related gene 1 (BRG1) or BRM, and an additional
9–12 proteins called BRM/BRG1 Associated Factors (BAFs) [89;
for review, see Ref. 90]. The function of SWI/SNF complexes can
vary depending on the complex components. Two major classes
of SWI/SNF complexes have been identiﬁed. The BAF complexes
(most similar to Saccharomyces SWI/SNF) contain either the BRG1
or BRM ATPase subunit together with one of two variant BAF250/
OSA/ARID1 subunits. These complexes contain a single bromodo-
main in their ATPase subunit. The choice of BAF250 subunit can
dramatically alter complex function, such as the opposing effects
of ARID1A versus ARID1B complexes in cell cycle control [81,82]
and the speciﬁc function of ARID1A in stem cell renewal [91].
The choice of ATPase may also be critical, because BRG1 tends to
be highly expressed in proliferating cells, whereas BRM is preferen-
tially expressed in terminally differentiated tissues [92], and be-
cause the regulation of speciﬁc target genes is sometimes
affected by only one ATPase or the other [93,94]. Furthermore,
Brg1/mice are embryonic lethal [95], whereas Brm/mice show
a relatively mild phenotype [96]. PBAF complexes (most similar to
yeast RSC) contain BRG1, but not BRM, lack BAF250 and contain a
BAF180/Polybromo subunit bearing six bromodomains.
Studies have shown that these variant SWI/SNF complexes have
distinct, but often overlapping functions [90]. Variant forms of
other subunits also exist, and show differential cell-type distribu-
tions and functions (such as the presence of BAF60a, but not
BAF60c in the esBAF complex, that is critical for stem cell renewal
[97]). The emerging model is that SWI/SNF complex composition
varies by tissue and cell type [89,95,98], and that the distinct com-
binations of subunits enable these variant complexes to interact
with distinct DNA-binding transcription factors and co-regulators,
or to interact with histones that bear speciﬁc modiﬁcations to carry
out tissue-speciﬁc, divergent functions.
The bromodomains in SWI/SNF complexes appear to play a crit-
ical role in maintaining the stable association of the complex with
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in an elegant set of in vitro experiments [99]. This mechanism is
also evidenced, in mammalian cells, by the requirement of
P/CAF-mediated acetylation to support SWI/SNF recruitment to
the myogenin promoter [100]. However, relatively little is known
about potential differential functions of the bromodomains in
BRG1, BRM or Polybromo.
Determination of genes that require SWI/SNF enzymes for prop-
er regulation has been accomplished in part by use of antibodies
that function in co-immunoprecipitation (co-IP) and chromatin
immunoprecipitation (ChIP) assays. These experiments show
SWI/SNF components localized with speciﬁc activators and/or at
speciﬁc gene sequences, indicating that the role of SWI/SNF in
co-activation and co-repression is mediated by direct recruitment
of the complex to target promoters [101–104]. SWI/SNF complexes
bind to a wide variety of transcription factors, acting either as co-
activators or co-repressors [for a recent review, see Ref. 105]. Of
particular relevance to adipogenic differentiation, hSWI/SNF com-
plexes bind to and serve as co-activators for many nuclear hor-
mone receptors, including estrogen, glucocorticoid, retinoic acid
receptor (RAR) families and PPARc [102,103,106–109]. SWI/SNF
and PPARc are crucial for adipogenesis, as discussed below. Se-
quence-speciﬁc DNA-binding transcription factors are required to
target individual adipogenic genes and marshal the transcriptional
program, but the general transcriptional factors and non-sequence
speciﬁc complexes, such as the bromodomain-containing chroma-
tin remodeling factors and co-activators, are also critical. It is not
well understood how these speciﬁc and general factors work to-
gether with chromatin remodeling enzymes on the promoters of
adipogenic genes.Table 1





NCoR PPAR-binding protein (PBP)
SMRT PPAR-interacting protein (PRIP)
Sirt 1 PGC-1,2
Factors shared between Brd2 complexes and PPARc complexes are shown in
boldface.6. Functions of PPARc and its transcriptional co-activators in
adipogenesis
Not only is transcriptional control of proliferation subject to
tight control, but differentiation must also be carefully regulated.
Adipocyte differentiation from ﬁbroblast-like progenitors, for
example, is regulated by two well-studied families of transcrip-
tional regulatory proteins: C/EBPs (CCAAT/enhancer binding pro-
tein) and PPARs (peroxisome proliferator-activated receptor),
especially PPARc, a master regulator of differentiation of white adi-
pose tissue (WAT) and brown adipose tissue (BAT) [110–113]. To
act as a transcription factor, PPARc forms a complex with the ret-
inoid X receptor (RXR) transcription factor [114–116]. Improper or
deﬁcient activation of PPARc is associated with insulin resistance
and T2D [117,118]. The transcriptional programs of adipogenesis
have been effectively reviewed [119].
Nuclear receptors like PPARc are Cys4-type Zn2+-ﬁnger tran-
scription factors. It has been proposed that this class prefers to
interact with BRG1 subunits of SWI/SNF [104,120]. Seminal studies
from the Imbalzano group [121] showed that the catalytic subunits
of the SWI/SNF complex, BRG1 and BRM, are required for induction
of adipogenic transcription programs. Speciﬁcally, they established
that general transcription factors assemble at the promoter of the
PPARc2 gene. Upon subsequent association of SWI/SNF and TFIIH
with the promoter, a preinitiation complex forms and is capable
of transcription. This topic has been recently reviewed [122,123].
It is now clear that SWI/SNF and associated bromodomain-contain-
ing co-activator complexes are crucial for PPARc function. Interest-
ingly, expression of dominant negative PPARc is capable of
partially reversing terminal adipogenesis [124], suggesting that
some basal form of ongoing chromatin maintenance or nucleo-
somal remodeling is required to maintain an adipogenic pattern
of gene expression. This would come at high energetic cost to the
adipocyte.PPARc co-activators, including members of the p160 family
[125,126] must be regulated in their association with the chroma-
tin-bound transcription complex. It is apparent that adipogenesis
or differentiation of adipose tissue from progenitors during devel-
opment could be severely affected by loss or dysregulation of this
association. We speculate that these associated co-activator and
SWI/SNF complexes localized on the chromatin of adipogenic
genes are partially disassembled upon cessation of the adipogenic
program. However, how this is achieved, to what extent, and the
signal transduction events that prompt complex disassembly are
obscure. For a model of this process, we have begun to analyze
the stoichiometry and kinetics of Brd2-dependent transcriptional
control of the cyclin A promoter [4], which requires complexes that
must be activated and inactivated each time the cell traverses the
cell cycle.
The dramatic adiposity of brd2 lo mice was completely unex-
pected. However, in retrospect the co-activator/co-repressor func-
tions of bromodomain proteins make sense as a mechanism for
regulating the adipogenic phenotype. The increased adipogenesis
of 3T3-L1 pre-adipocytes in which Brd2 was knocked down [3]
suggests PPARc interactions with Brd2 are crucial. In addition,
two important transcriptional targets of PPARc and its co-activator
PGC-1a are the genes that encode mitochondrial uncoupling pro-
tein-1 and -2 (ucpl, ucp2), which have been linked to obesity
[127] in mice [128] and humans [129] and are important for ther-
mogenesis in BAT. We noted that both ucp1 and 2 were dramati-
cally elevated in brd2 lo mice [3]. Intriguingly, PCG-1a binds a
transcriptional co-activator/co-repressor complex [130,131] that
contains the Mediator complex [132] and Brd2 [4,133–135]. These
observations reinforce the hypothesis that Brd2 levels regulate the
transcription of genes that are targets of the PPARc/PCG-1 family.
Certain crucial transcription co-factors are shared between Brd2
transcription complexes [4,5,48] (Fig. 1) and PPARc-containing
complexes (Table 1; common factors shown in bold) [123]. Net co-
activation/co-repression depends on the relative abundance, tar-
geting and activity of these associated factors [59] and their ability
to switch the chromatin status of key metabolic genes. This insight
suggested two easily testable hypotheses: that (1) Brd2 and PPARc
interact, either directly through protein–protein association, or
indirectly through association in a ternary complex, and that (2)
a drop in Brd2 levels in certain cell types, such as the pre-adipo-
cyte, derepresses PPARc-regulated transcription. Co-immunopre-
cipitation experiments showed that indeed, Brd2 and PPARc
associate, and Brd2 opposes the action of PPARc on PPAR-respon-
sive transcriptional elements in DNA [3]. Interestingly, mice har-
boring a knock-in mutation of ‘silencing mediator of retinoid and
thyroid hormone receptors’ (SMRT), a nuclear co-repressor thought
normally to antagonize PPARc-directed transcription, exhibit a
pro-adipogenic phenotype [136], as do mice harboring a knockout
of estrogen receptor b [137]. This phenotype shares certain fea-
tures with Brd2 knockdown, particularly the lower threshold for
a PPARc-directed program of transcription. This pattern also resembles
the insulin-sensitizing action of glitazones and thiazolidinediones
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vel, useful, ‘druggable’ therapeutic target for insulin resistance. In
addition, the thyroid hormone receptor-associated protein
(TRAP)220 component of the Mediator complex (encoded by
MED1) is important for PPARc-directed adipogenesis [139]. The
observation that Brd2 associates with a number of components
of the Mediator complex [4] suggests that PPARc and Brd2 may
be functionally linked through Mediator. Thus, it will be important
to verify the presence on chromatin of the Brd2 complex factors
shared with PPARc-associated complexes, and then test their func-
tion individually to understand the combined functions of Brd2
and PPARc in transcriptional regulation of adipogenesis. Given
the failure of intensive effort to identify an obvious endogenous li-
gand for PPARc, we can reasonably speculate that speciﬁc post-
translational modiﬁcations in response to nutritional signal trans-
duction, such as phosphorylation of co-repressor proteins or acet-
ylation/ubiquitylation of histones, might behave as a ‘pseudo-
ligand’ for shifting co-repressor complex function and enable
PPARc-directed adipogenesis. If so, Brd2 may be poised to respond
to these signals either as a target for modiﬁcation or as a ‘reader’ of
the resulting modiﬁcations, especially histone acetylation.7. A model for the role of bromodomain proteins in adipocyte
differentiation
Recent studies have shown that Brd2 cooperates with E2F1, sta-
bilizing a transcriptional activation complex on acetylated chroma-
tin at cyclin A. This complex also contains SWI/SNF, the association
of which will be stabilized both through interaction with Brd2 and
via binding of the bromodomain in its ATPase subunit to acetylated
chromatin. By contrast, a combination of RB binding to E2F1 (that
potentially recruits the inactivating ARID1A form of SWI/SNF), loss
of cyclin A promoter acetylation and loss of Brd2 would silence
cyclin A and slow growth of pre-adipocytes. In addition to the slow-
ing of growth, adipocyte differentiation requires the upregulation
of PPARc, which requires SWI/SNF for increased transcription.
PPARc activation of its target genes is also likely to require
SWI/SNF, although the speciﬁc variant complex involved has not
been identiﬁed. Importantly, however, Brd2 can inhibit transacti-
vation by PPARc [3]. Thus, Brd2 is required both to activate genes
that enable growth and to repress differentiation-speciﬁc genes in
pre-adipocytes. Accordingly, it is not surprising that deletion of
Brd2 leads to a near-complete elimination of mature adipocytes.8. Important outstanding issues
1. Signal transduction and speciﬁcity. The mechanisms by which
signal transduction pathways instruct the chromatin remodel-
ing machinery to conduct an adipogenic program are very
poorly understood. The notion that chromatin remodeling
machines can function as effectors of signal transduction, par-
ticularly of mitogenic signals, has been discussed with respect
to Mediator [134] and hSWI/SNF [140,141]. For example, mito-
genic signals through the ras pathway [142] or inﬂammatory
signals through the TLR pathway [143,144] convey information
to chromatin to create a coherent transcriptional state that is
also reversible. Conversely, it is reasonable to hypothesize that
in response to an adipogenic differentiation signal, a specialized
cell mobilizes a MDa transcriptional apparatus at a limited
number of genes. This restricted response – only a few ‘imme-
diate early’ adipogenic promoters – could explain why the glo-
bal disruption of so fundamental a transcriptional cofactor as
Brd2 generates a coherent response on PPARc-responsive pro-
moters and a clear, adipogenic transcriptional program in a
pre-adipocyte. Most progenitor cells, such as pre-adipocytes,are already primed for a speciﬁc fate, thus, manipulation of glo-
bal transcriptional and chromatin programs does not create
transcriptional confusion, because the map of cell fate is
restricted. It will be important to learn how, upon cell cycle exit
and induction of differentiation, chromatin in the adipocyte
resolves the differential responses to a combination of mito-
genic and differentiation-promoting signal transduction path-
ways. It also remains to be explored whether epigenetic
predetermination of adipogenic promoters is a major mecha-
nism that deﬁnes the cell fate of the pre-adipocyte. More
generally, a better, comprehensive knowledge of the signal
transduction-mediated mechanisms of priming in progenitor
cells will be critical if we wish to understand how lineage-spe-
ciﬁc transcription factors establish cell fate.
2. Functional shifts in chromatin remodeling and histone modiﬁcation
complex composition. Biochemical studies of SWI/SNF com-
plexes sometimes identify BRG1 and BRM subunits associated
with the same locus [121], reﬂecting the view that these sub-
units identify complexes that exhibit a combination of overlap-
ping and speciﬁc functions. Differential recruitment of SWI/SNF
subunits BAF155 and BAF170 to the same promoter in response
to estrogen determines subsequent recruitment of a co-activa-
tor HAT or a co-repressor HDAC [145], suggesting that different
mechanisms of PPARc activation (which may include signal
transduction pathways or as-yet unidentiﬁed endogenous
ligands) could differentially regulate transcription factor/chro-
matin complexes formed during adipogenesis.
The dramatic adipogenic phenotype of Brd2 deﬁciency
strongly suggests that Brd2 and its associated bromodomain-
containing transcriptional co-regulators (including SWI/SNF)
are central to the decision to undergo adipogenic differentiation.
During this process, the chromatin-associated SWI/SNF com-
plexes likely change character in a coordinated fashion. These
shifts will be most directly measurable with analysis of chroma-
tin-modifying activities, alongwithDNA accessibility, associated
with proliferative and adipogenic genes during adipogenesis (i.e.
at the endof the clonal expansion) in3T3-L1adipocytes that have
been induced to undergo adipogenic differentiation.
It appears that E2Fs govern a link between proliferative sig-
naling pathways and terminal adipocyte differentiation. E2Fs
trigger clonal expansion, then, through RB-mediated repression
and replacement of pro-proliferative E2Fs with pro-differentia-
tion E2Fs, coherently switch a variety of promoters to the new
program. Apart from the proposed role of E2F-1 in PPARc1 tran-
scription, to switch between proliferative, clonal expansion and
terminal adipocyte differentiation through control of PPARc lev-
els [146], reviewed in [119], it is reasonable to hypothesize that
reduced levels of Brd2 or a related bromodomain protein repro-
grams a panel of target genes, analogous to the result of swi/snf
mutation in Saccharomyces [88], transcriptionally repressing
the proliferative genes [5] and activating the adipogenic genes
[3]. Likewise, transcriptionally activating SWI/SNF complexes
may need to shift character to transcriptional repression com-
plexes on the relevant promoters. It is unclear whether this
switch would occur by swapping out subunits on chromatin-
boundSWI/SNFor by exchangingoneentire complex for another.
However, given the rapid exchange seen for most transcription
factors on and off chromatin [for review, see Ref. [147]] together
with the strong association of SWI/SNF complex subunits in bio-
chemical studies, the latterpossibility seemsmost likely [148].As
discussed above, experiments in the 3T3-L1model will be useful
to deﬁne these mechanisms. It will be expected that patterns of
histone and DNAmethylation and acetylation, DNA accessibility,
DNAse hypersensitivity and transcript levels will follow suit and
reﬂect the differential functions of the variant chromatin-bound
complexes.
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cell fate used an RNAi screen in Drosophila to identify candidate
obesity genes and discovered an important, previously unap-
preciated role for hedgehog signal transduction [149]. Signiﬁ-
cantly, reported activators of the fat-speciﬁc obesity pathway
included Nejire [a ﬂy homolog of the well-known HAT p300/
CREB (cyclic AMP-responsive element binding) binding protein
(CBP)]; repressors included trr (trithorax-related histone meth-
yltransferase), CG3075 (histone H2A), Su(fu) (an mSin3 co-
repressor) and slmb (required for E2F function). These factors
implicate chromatin modiﬁcation in adipogenic transcriptional
programs and should be studied in detail in mouse models. In
this regard, developmental regulators such as the bone morpho-
genetic proteins (BMPs) [150] with morphogen roles ﬁrst iden-
tiﬁed in Drosophila [151] and transcriptional co-activators such
as PRDM16 [152] and PGC-1 [153] have newfound signiﬁcance
in adipogenic transcriptional programs and cell fate, particu-
larly the crucial function of BMP-7 in BAT adipogenesis [154].
However, very little is known about how these developmental
factors communicate with nucleosomes and chromatin remod-
eling machinery during an adipogenic program in adult progen-
itor cells.
4. Maternal effect on adipogenesis. The Drosophila homolog of Brd2,
fs(1)h, is a maternal effect gene [23,30,31], which suggests the
possibility that adipogenic transcriptional programs in humans
are inﬂuenced by maternal effect inheritance of BRD2. Brd2
remains mitotically associated with chromatin [6], and Brd4
tethers virus episomes to host mitotic chromatin across cell
divisions [155]. This behavior suggests a role for dual bromod-
omain proteins in inheritance, not only of speciﬁc histone mod-
iﬁcations from one cell generation to the next, but also of
chromatin-bound complexes, which likely has signiﬁcance for
epigenetic inheritance of predisposition to adiposity. Convinc-
ing evidence from epidemiological study of the Dutch ‘Hunger
Winter’ of 1944–1945 establishes an environmental maternal
effect of starvation during gestation. Speciﬁcally, maternal hun-
ger promotes insulin insensitivity, obesity, an atherogenic lipid
proﬁle and elevates CVD risk in the surviving children as they
age [156]. A number of animal models explore the effect of ges-
tational stress on obesity, hypertension, insulin resistance and
hyperinsulinemia in progeny [recently reviewed in 157]. How-
ever, there has been insufﬁcient study of geneticmaternal effect
on obesity. It is likely that alleles of chromatin modiﬁcation
genes, or genes of the class II Major Histocompatibility Com-
plex, within which BRD2 resides, will be found to play a role
in maternally inherited patterns of human adipogenesis and
insulin sensitivity, independent of environment and nutrition
status.
9. Future directions
Deﬁciency of Brd2, a gene that encodes a dual bromodomain
protein in mice, generates an unexpected and dramatic adipogenic
phenotype, revealing a pathway of transcriptional co-repression
and chromatin modiﬁcation that normally opposes the action of
PPARc. Heterozygous brd2 lo mice develop severe obesity but, sur-
prisingly, completely avoid insulin resistance. These mice may pro-
vide a useful model for decoupling these two aspects of metabolic
syndrome. The Drosophila homolog of Brd2, female sterile (1) home-
otic, is a maternal effect, developmental gene and upstream activa-
tor of the trithorax complex, which opposes Polycomb action.
These surprising connections suggest that research effort in hu-
mans that focuses on the adipocyte-speciﬁc functions of develop-
mental and patterning genes will be fruitful, because the size and
health of adipose tissue depots, body mass index, insulin sensitiv-
ity and WAT/BAT speciﬁcation from progenitors are all likely to beaffected by this pathway. This area of investigation is surprisingly
underdeveloped, yet is of great medical signiﬁcance because of the
potential for new mechanistic insight into the ‘metabolically
healthy but obese’ (MHO) human phenotype [158], which exhibits
a reduced CVD risk and a diminished inﬂammatory proﬁle [159].
Novel developmental pathways could be exploited to design a next
generation of insulin-sensitizing drugs to treat obesity and its co-
morbidities, or re-direct energy storage from undesirable, central
obesity to peripheral, subcutaneous depots of adipose tissue. In
addition, this work highlights the connections between chromatin
status, nucleosome positioning, histone modiﬁcation and adipo-
genic transcription programs. Particularly, research effort should
focus on the critical role of bromodomain-containing protein com-
plexes, such as Brd2, SWI/SNF and their associated co-activator/co-
repressor factors, in transcriptional reprogramming from prolifera-
tion in the pre-adipocyte to differentiation in the adipocyte. These
epigenetic mechanisms have an importance at least equal to line-
age-speciﬁc transcription factors in the determination of cell fate.
Acknowledgements
This work is supported by grants from the National Institutes of
Health (NCI and NIDDK), the American Cancer Society and the Leu-
kemia and Lymphoma Society. We thank our colleagues for their
elegant and detailed work that explores the transcriptional pro-
grams of adipogenesis; space constraints do not permit compre-
hensive citation. Any omissions and errors are of course our own.
References
[1] Haslam, D.W. and James, W.P. (2009) Obesity. Lancet 366, 1197–1209.
[2] Hossain, P., Kawar, B. and El Nahas, M. (2007) Obesity and diabetes in the
developing world – a growing challenge. N. Engl. J. Med. 356, 213–215.
[3] Wang, F., Liu, H., Blanton, W.P., Belkina, A., LeBrasseur, N.K. and Denis, G.V.
(2010) Brd2 disruption in mice causes severe obesity without type 2 diabetes.
Biochem. J. 425, 71–83.
[4] Denis, G.V., McComb, M.E., Faller, D.V., Sinha, A., Romesser, P.B. and Costello,
C.E. (2006) Identiﬁcation of transcription complexes that contain the dual
bromodomain protein Brd2 and chromatin remodeling machines. J. Proteome
Res. 5, 502–511.
[5] Sinha, A., Faller, D.V. and Denis, G.V. (2005) Bromodomain analysis of Brd2-
dependent transcriptional activation of cyclin A. Biochem. J. 387, 257–269.
[6] Kanno, T., Kanno, Y., Siegel, R.M., Jang, M.K., Lenardo, M.J. and Ozato, K. (2004)
Selective recognition of acetylated histones by bromodomain proteins
visualized in living cells. Mol. Cell 13, 33–43.
[7] Ornaghi, P., Ballario, P., Lena, A.M., González, A. and Filetici, P. (1999) The
bromodomain of Gcn5p interacts in vitro with speciﬁc residues in the N
terminus of histone H4. J. Mol. Biol. 287, 1–7.
[8] Dhalluin, C., Carlson, J.E., Zeng, L., He, C., Aggarwal, A.K. and Zhou, M.M.
(1999) Structure and ligand of a histone acetyltransferase bromodomain.
Nature 399, 491–496.
[9] Nakamura, Y., Umehara, T., Nakano, K., Jang, M.K., Shirouzu, M., Morita, S.,
Uda-Tochio, H., Hamana, H., Terada, T., Adachi, N., Matsumoto, T., Tanaka, A.,
Horikoshi, M., Ozato, K., Padmanabhan, B. and Yokoyama, S. (2007) Crystal
structure of the human BRD2 bromodomain: insights into dimerization and
recognition of acetylated histone H4. J. Biol. Chem. 282, 4193–4201.
[10] Umehara, T., Nakamura, Y., Jang, M.K., Nakano, K., Tanaka, A., Ozato, K.,
Padmanabhan, B. and Yokoyama, S. (2010) Structural basis for acetylated
histone H4 recognition by the human BRD2 bromodomain. J. Biol. Chem. 285,
7610–7618.
[11] Thorpe, K.L., Gorman, P., Thomas, C., Sheer, D., Trowsdale, J. and Beck, S.
(1997) Chromosomal localization, gene structure and transcription pattern of
the ORFXgene, a homologue of the MHC-linked RING3 gene. Gene 200, 177–
183.
[12] LeRoy, G., Rickards, B. and Flint, S.J. (2008) The double bromodomain proteins
Brd2 and Brd3 couple histone acetylation to transcription. Mol. Cell 30, 51–
60.
[13] Dey, A., Chitsaz, F., Abbasi, A., Misteli, T. and Ozato, K. (2003) The double
bromodomain protein Brd4 binds to acetylated chromatin during interphase
and mitosis. Proc. Natl. Acad. Sci. USA 100, 8758–8763.
[14] Shang, E., Salazar, G., Crowley, T.E., Wang, X., Lopez, R.A., Wang, X. and
Wolgemuth, D.J. (2004) Identiﬁcation of unique, differentiation stage-
speciﬁc patterns of expression of the bromodomain-containing genes
Brd2, Brd3, Brd4, and Brdt in the mouse testis. Gene Expr. Patterns 4,
513–519.
[15] Lee, A.Y. and Chiang, C.M. (2009) Chromatin adaptor Brd4 modulates E2
transcription activity and protein stability. J. Biol. Chem. 284, 2778–2786.
3266 G.V. Denis et al. / FEBS Letters 584 (2010) 3260–3268[16] Jones, M.H., Numata, M. and Shimane, M. (1997) Identiﬁcation and
characterization of BRDT: a testis-speciﬁc gene related to the
bromodomain genes RING3 and Drosophila fsh. Genomics 45, 529–534.
[17] Jacobson, R.H., Ladurner, A.G., King, D.S. and Tjian, R. (2000) Structure and
function of a human TAFII250 double bromodomain module. Science 288,
1422–1425.
[18] Liu, Y., Wang, X., Zhang, J., Huang, H., Ding, B., Wu, J. and Shi, Y. (2008)
Structural basis and binding properties of the second bromodomain of Brd4
with acetylated histone tails. Biochemistry 47, 6403–6417.
[19] Lygerou, Z., Conesa, C., Lesage, P., Swanson, R.N., Ruet, A., Carlson, M.,
Sentenac, A. and Seraphin, B. (1994) The yeast BDF1 gene encodes a
transcription factor involved in the expression of a broad class of genes
including snRNAs. Nucl. Acids Res. 22, 5332–5340.
[20] Chua, P. and Roeder, G.S. (1995) Bdf1, a yeast chromosomal protein required
for sporulation. Mol. Cell. Biol. 15, 3685–3696.
[21] Ladurner, A.G., Inouye, C., Jain, R. and Tjian, R. (2003) Bromodomains mediate
an acetyl-histone encoded antisilencing function at heterochromatin
boundaries. Mol. Cell 11, 365–376.
[22] Airoldi, C.A., Rovere, F.D., Falasca, G., Marino, G., Kooiker, M., Altamura, M.M.,
Citterio, S. and Kater, M.M. (2010) The Arabidopsis BET bromodomain factor
GTE4 is involved in maintenance of the mitotic cell cycle during plant
development. Plant Physiol. 152, 1320–1334.
[23] Digan, M.E., Haynes, S.R., Mozer, B.A., Dawid, I.B., Forquignon, F. and Gans, M.
(1986) Genetic and molecular analysis of fs(1)h, a maternal effect homeotic
gene in Drosophila. Dev. Biol. 114, 161–169.
[24] Haynes, S.R., Mozer, B.A., Bhatia-Dey, N. and Dawid, I.B. (1989) The Drosophila
fsh locus, a maternal effect gene, encodes apparent transmembrane proteins.
Dev. Biol. 134, 246–257.
[25] Chang, Y.L., King, B., Lin, S.C., Kennison, J.A. and Huang, D.H. (2007) A double-
bromodomain protein, FSH-S, activates the homeotic gene ultrabithorax
through a critical promoter-proximal region. Mol. Cell. Biol. 27, 5486–5498.
[26] Shibata, Y., Takeshita, H., Sasakawa, N. and Sawa, H. (2010) Double
bromodomain protein BET-1 and MYST HATs establish and maintain stable
cell fates in C. elegans. Development 137, 1045–1053.
[27] Toyama, R., Rebbert, M.L., Dey, A., Ozato, K. and Dawid, I.B. (2008) Brd4
associates with mitotic chromosomes throughout early zebraﬁsh
embryogenesis. Dev. Dyn. 237, 1636–1644.
[28] Forquignon, F. (1981) A maternal effect mutation leading to deﬁciencies of
organs and homeotic transformations in the adults of Drosophila. Wilhelm
Roux’s Arch. Dev. Biol. 190, 132–138.
[29] Gans, M., Forquignon, F. and Masson, M. (1980) The role of dosage in the
region 7D1–7D5-6 of the X chromosome in the production of homeotic
transformations in Drosophila melanogaster. Genetics 96, 887–902.
[30] Mozer, B.A. and Dawid, I.B. (1989) Cloning and molecular characterization of
the trithorax locus of Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 86,
3738–3742.
[31] Huang, D.H. and Dawid, I.B. (1990) The maternal-effect gene fsh is essential
for the speciﬁcation of the central region of the Drosophila embryo. New Biol.
2, 163–170.
[32] D’Costa, A., Reifegerste, R., Sierra, S. and Moses, K. (2006) The Drosophila
ramshackle gene encodes a chromatin-associated protein required for cell
morphology in the developing eye. Mech. Dev. 123, 591–604.
[33] Shang, E., Nickerson, H.D., Wen, D., Wang, X. and Wolgemuth, D.J. (2007) The
ﬁrst bromodomain of Brdt, a testis-speciﬁc member of the BET sub-family of
double-bromodomain containing proteins, is essential for male germ cell
differentiation. Development 134, 3507–3715.
[34] Shang, E., Wang, X., Wen, D., Greenberg, D.A. and Wolgemuth, D.J. (2009)
Double bromodomain-containing gene Brd2 is essential for embryonic
development in mouse. Dev. Dyn. 238, 908–917.
[35] Gans, M., Audit, C. and Masson, M. (1975) Isolation and characterization of
sex-linked female-sterile mutants in Drosophila melanogaster. Genetics 81,
683–704.
[36] Mazo, A.M., Huang, D.H., Mozer, B.A. and Dawid, I.B. (1990) The trithorax
gene, a trans-acting regulator of the bithorax complex in Drosophila,encodes
a protein with zinc-binding domains. Proc. Natl. Acad. Sci. USA 87, 2112–
2116.
[37] French, C.A., Miyoshi, I., Aster, J.C., Kubonishi, I., Kroll, T.G., Dal Cin, P., Vargas,
S.O., Perez-Atayde, A.R. and Fletcher, J.A. (2001) BRD4 bromodomain gene
rearrangement in aggressive carcinoma with translocation t(15;19). Am. J.
Pathol. 159, 1987–1992.
[38] Wu, S.Y. and Chiang, C.M. (2007) The double bromodomain-containing
chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 282,
13141–13145.
[39] Farina, A., Hattori, M., Qin, J., Nakatani, Y., Minato, N. and Ozato, K. (2004)
Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its
activity and subcellular localization. Mol. Cell. Biol. 24, 9059–9069.
[40] Greenwald, R., Tumang, J.R., Sinha, A., Currier, N., Cardiff, R.D., Rothstein, T.L.,
Faller, D.V. and Denis, G.V. (2004) Eu-BRD2 transgenic mice develop B cell
lymphoma and leukemia. Blood 103, 1475–1484.
[41] Dey, A., Nishiyama, A., Karpova, T., McNally, J. and Ozato, K. (2009) Brd4
marks select genes on mitotic chromatin and directs postmitotic
transcription. Mol. Biol. Cell 20, 4899–4909.
[42] Dey, A., Ellenberg, J., Farina, A., Coleman, A.E., Maruyama, T., Sciortino, S.,
Lippincott-Schwartz, J. and Ozato, K. (2000) A bromodomain protein, MCAP,
associates with mitotic chromosomes and affects G(2)-to-M transition. Mol.
Cell. Biol. 20, 6537–6549.[43] Houzelstein, D., Bullock, S.L., Lynch, D.E., Grigorieva, E.F., Wilson, V.A. and
Beddington, R.S.P. (2002) Growth and early postimplantation defects in mice
deﬁcient for the bromodomain-containing protein Brd4. Mol. Cell. Biol. 22,
3794–3802.
[44] Ruppert, S., Wang, E.H. and Tjian, R. (1993) Cloning and expression of human
TAFII250: a TBP-associated factor implicated in cell-cycle regulation. Nature
362, 175–179.
[45] Wang, E.H., Zou, S. and Tjian, R. (1997) TAFII250-dependent transcription of
cyclin A is directed by ATF activator proteins. Genes Dev. 11, 2658–2669.
[46] Denis, G.V. and Green, M.R. (1996) A novel, mitogen-activated nuclear
kinase is related to a Drosophila developmental regulator. Genes Dev. 10,
261–271.
[47] Ostrowski, J., Florio, S.K., Denis, G.V., Suzuki, H. and Bomsztyk, K. (1998)
Stimulation of p85/RING3 kinase in multiple organs after systemic
administration of mitogens into mice. Oncogene 16, 1223–1227.
[48] Denis, G.V., Vaziri, C., Guo, N. and Faller, D.V. (2000) RING3 kinase
transactivates promoters of cell cycle regulatory genes through E2F. Cell
Growth Diff. 11, 417–424.
[49] Lenburg, M., Sinha, A., Faller, D.V. and Denis, G.V. (2007) Tumor-speciﬁc and
proliferation-speciﬁc gene expression typiﬁes murine transgenic B cell
lymphomagenesis. J. Biol. Chem. 282, 4803–4811.
[50] Romesser, P.B., Perlman, D.H., Faller, D.V., Costello, C.E., McComb, M.E. and
Denis, G.V. (2009) Development of a malignancy-associated proteomic
signature for diffuse large B cell lymphoma. Am. J. Pathol. 175, 25–35.
[51] Jeanmougin, F., Wurtz, J.-M., Le Douarin, B., Chambon, P. and Losson, R.
(1997) The bromodomain revisited. Trends Biochem. Sci. 22, 151–153.
[52] Winston, F. and Allis, C.D. (1999) The bromodomain: a chromatin-targeting
module? Nat. Struct. Biol. 6, 601–604.
[53] Filetici, P., Ornaghi, P. and Ballario, P. (2001) The bromodomain: a chromatin
browser? Front. Biosci. 6, D866–D876.
[54] Sobulo, O.M., Borrow, J., Tomek, R., Reshmi, S., Harden, A., Schlegelberger, B.,
Housman, D., Doggett, N.A., Rowley, J.D. and Zeleznik-Le, N.J. (1997) MLL is
fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid
leukemia with a t(11;16)(q23;p133). Proc. Natl. Acad. Sci. USA 94, 8732–
8737.
[55] Lavau, C., Du, C., Thirman, M. and Zeleznik-Le, N. (2000) Chromatin-related
properties of CBP fused to MLL generate a myelodysplastic-like syndrome
that evolves into myeloid leukemia. EMBO J. 19, 4655–4664.
[56] Panagopoulos, I., Fioretos, T., Isaksson, M., Samuelsson, U., Billström, R.,
Strömbeck, B., Mitelman, F. and Johansson, B. (2001) Fusion of the MORF and
CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum. Mol.
Genet. 10, 395–404.
[57] French, C.A., Miyoshi, I., Kubonishi, I., Grier, H.E., Perez-Atayde, A.R. and
Fletcher, J.A. (2003) BRD4-NUT fusion oncogene: a novel mechanism in
aggressive carcinoma. Cancer Res. 63, 304–307.
[58] Haynes, S.R., Dollard, C., Winston, F., Beck, S., Trowsdale, J. and Dawid, I.B.
(1992) The bromodomain: a conserved sequence found in human, Drosophila
and yeast proteins. Nucl. Acids Res. 20, 2603.
[59] Denis, G.V. (2001) Bromodomain motifs and ‘‘scaffolding? Front. Biosci. 6,
D1065–D1068.
[60] Tamkun, J.W., Deuring, R., Scott, M.P., Kissinger, M., Pattatucci, A.M.,
Kaufman, T.C. and Kennison, J.A. (1992) brahma: a regulator of Drosophila
homeotic genes structurally related to the yeast transcriptional activator
SNF2/SWI2. Cell 68, 561–572.
[61] Randazzo, F.M., Khavari, P., Crabtree, G., Tamkun, J. and Rossant, J. (1994)
brg1: a putative murine homologue of the Drosophila brahma gene, a
homeotic gene regulator. Dev. Biol. 161, 229–242.
[62] Gu, Y., Nakamura, T., Alder, H., Prasad, R., Canaani, O., Cimino, G., Croce, C.M.
and Canaani, E. (1992) The t(4;11) chromosomal translocation of human
acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the
AF-4 gene. Cell 71, 701–708.
[63] Tkachuk, D.C., Kohler, S. and Cleary, M.L. (1992) Involvement of a homolog of
Drosophila trithorax by 11q23 chromosomal translocations in acute
leukemias. Cell 71, 691–700.
[64] Reisman, D.N., Strobeck, M.W., Betz, B.L., Sciariotta, J., Funkhouser Jr., W.,
Murchardt, C., Yaniv, M., Sherman, L.S., Knudsen, E.S. and Weissman, B.E.
(2002) Concomitant down-regulation of BRM and BRG1 in human tumor cell
lines: differential effects on RB-mediated growth arrest vs CD44 expression.
Oncogene 21, 1196–1207.
[65] Hendricks, K.B., Shanahan, F. and Lees, E. (2004) Role for BRG1 in cell cycle
control and tumor suppression. Mol. Cell. Biol. 24, 362–376.
[66] Florence, B. and Faller, D.V. (2001) You bet-cha: a novel family of
transcriptional regulators. Front. Biosci. 6, D1008–D1018.
[67] de la Cruz, X., Lois, S., Sanchez-Molina, S. and Martinez-Balbas, M.A. (2005)
Do protein motifs read the histone code? Bioessays 27, 164–175.
[68] Mujtaba, S., Zeng, L. and Zhou, M.M. (2007) Structure and acetyl-lysine
recognition of the bromodomain. Oncogene 26, 5521–5527.
[69] Angus, S.P., Fribourg, A.F., Markey, M.P., Williams, S.L., Horn, H.F., DeGregori,
J., Kowalik, T.F., Fukasawa, K. and Knudsen, E.S. (2002) Active RB elicits late
G1/S inhibition. Exp. Cell Res. 276, 201–213.
[70] Frankfurt, O. and Tallman, M.S. (2007) Growth factors in leukemia. J. Natl.
Compr. Canc. Netw. 5, 203–215.
[71] Brandts, C.H., Berdel, W.E. and Serve, H. (2007) Oncogenic signaling in acute
myeloid leukemia. Curr. Drug Targets 8, 237–246.
[72] Moore, M.A. (2005) Converging pathways in leukemogenesis and stem cell
self-renewal. Exp. Hematol. 33, 719–737.
G.V. Denis et al. / FEBS Letters 584 (2010) 3260–3268 3267[73] Mongan, N.P. and Gudas, L.J. (2007) Diverse actions of retinoid receptors in
cancer prevention and treatment. Differentiation 75, 853–870.
[74] Berman, J.N. and Look, A.T. (2007) Targeting transcription factors in acute
leukemia in children. Curr. Drug Targets 8, 727–737.
[75] Trouche, D., Le Chalony, C., Muchardt, C., Yaniv, M. and Kouzarides, T. (1997)
RB and hbrm cooperate to repress the activation functions of E2F1. Proc. Natl.
Acad. Sci. USA 94, 11268–11273.
[76] Zhang, H.S., Dahiya, A., Gavin, M., Ma, D., Postigo, A.A., Harbour, J.W., Luo, R.X.
and Dean, D.C. (2000) Exit from G1 and S phase of the cell cycle is regulated
by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF.
Cell 101, 79–89.
[77] Stiegler, P., De Luca, A., Bagella, L. and Giordano, A. (1998) The COOH-
terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1),
enhancing transcriptional repression of the E2F-dependent cyclin A
promoter. Cancer Res. 58, 5049–5052.
[78] Brehm, A., Miska, E.A., McCance, D.J., Reid, J.L., Bannister, A.J. and Kouzarides,
T. (1998) Retinoblastoma protein recruits histone deacetylase to repress
transcription. Nature 391, 597–601.
[79] Magnaghi-Jaulin, L., Groisman, R., Naguibneva, I., Robin, P., Lorain, S., Le
Villain, J.P., Troalen, F., Trouche, D. and Harel-Bellan, A. (1998)
Retinoblastoma protein represses transcription by recruiting a histone
deacetylase. Nature 391, 601–605.
[80] Ferreira, R., Magnaghi-Jaulin, L., Robin, P., Harel-Bellan, A. and Trouche, D.
(1998) The three members of the pocket proteins family share the ability to
repress E2F activity through recruitment of a histone deacetylase. Proc. Natl.
Acad. Sci. USA 95, 10493–10498.
[81] Nagl Jr., N.G., Zweitzig, D.R., Thimmapaya, B., Beck Jr., G.R. and Moran, E.
(2006) The c-myc gene is a direct target of mammalian SWI/SNF-related
complexes during differentiation-associated cell cycle arrest. Cancer Res. 66,
1289–1293.
[82] Nagl Jr., N.G., Wang, X., Patsialou, A., Van Scoy, M. and Moran, E. (2007)
Distinct mammalian SWI/SNF chromatin remodeling complexes with
opposing roles in cell-cycle control. EMBO J. 26, 752–763.
[83] Florence, B.L. and Faller, D.V. (2008) Drosophila female sterile (1) homeotic is a
multifunctional transcriptional regulator that is modulated by Ras signaling.
Dev. Dyn. 237, 554–564.
[84] Peterson, C.L. and Workman, J.L. (2000) Promoter targeting and chromatin
remodeling by the SWI/SNF complex. Curr. Opin. Genet. Dev. 10, 187–192.
[85] Hassan, A.H., Neely, K.E., Vignali, M., Reese, J.C. and Workman, J.L. (2001)
Promoter targeting of chromatin-modifying complexes. Front. Biosci. 6,
1054–1064.
[86] Schnitzler, G.R. (2008) Control of nucleosome positions by DNA sequence and
remodeling machines. Cell. Biochem. Biophys. 51, 67–80.
[87] Burns, L.G. and Peterson, C.L. (1997) The yeast SWI–SNF complex facilitates
binding of a transcriptional activator to nucleosomal sites in vivo. Mol. Cell.
Biol. 17, 4811–4819.
[88] Holstege, F.C., Jennings, E.G., Wyrick, J.J., Lee, T.I., Hengartner, C.J., Green, M.R.,
Golub, T.R., Lander, E.S. and Young, R.A. (1998) Dissecting the regulatory
circuitry of a eukaryotic genome. Cell 95, 717–728.
[89] Wang, W., Côte, J., Xue, Y., Zhou, S., Khavari, P.A., Biggar, S.R., Muchardt, C.,
Kalpana, G.V., Goff, S.P., Yaniv, M., Workman, J.L. and Crabtree, G.R. (1996)
Puriﬁcation and biochemical heterogeneity of the mammalian SWI–SNF
complex. EMBO J. 15, 5370–5382.
[90] Mohrmann, L. and Verrijzer, C.P. (2005) Composition and functional
speciﬁcity of SWI2/SNF2 class chromatin remodeling complexes. Biochim.
Biophys. Acta 1681, 59–73.
[91] Gao, X., Tate, P., Hu, P., Tjian, R., Skarnes, W.C. and Wang, Z. (2008) ES cell
pluripotency and germ-layer formation require the SWI/SNF chromatin
remodeling component BAF250a. Proc. Natl. Acad. Sci. USA 105, 6656–6661.
[92] Reisman, D.N., Sciarrotta, J., Bouldin, T.W., Weissman, B.E. and Funkhouser,
W.K. (2005) The expression of the SWI/SNF ATPase subunits BRG1 and BRM
in normal human tissues. Appl. Immunohistochem. Mol. Morphol. 13, 66–74.
[93] Lemon, B., Inouye, C., King, D.S. and Tjian, R. (2001) Selectivity of chromatin-
remodelling cofactors for ligand-activated transcription. Nature 414, 924–
928.
[94] Mizutani, T., Ito, T., Nishina, M., Yamamichi, N., Watanabe, A. and Iba, H.
(2002) Maintenance of integrated proviral gene expression requires Brm, a
catalytic subunit of SWI/SNF complex. J. Biol. Chem. 277, 15859–15864.
[95] Bultman, S., Gebuhr, T., Yee, D., La Mantia, C., Nicholson, J., Gilliam, A.,
Randazzo, F., Metzger, D., Chambon, P., Crabtree, G. and Magnuson, T. (2000)
A Brg1 null mutation in the mouse reveals functional differences among
mammalian SWI/SNF complexes. Mol. Cell 6, 1287–1295.
[96] Reyes, J.C., Barra, J., Muchardt, C., Camus, A., Babinet, C. and Yaniv, M. (1998)
Altered control of cellular proliferation in the absence of mammalian brahma
(SNF2alpha). EMBO J. 17, 6979–6991.
[97] Ho, L., Ronan, J.L., Wu, J., Staahl, B.T., Chen, L., Kuo, A., Lessard, J., Nesvizhskii,
A.I., Ranish, J. and Crabtree, G.R. (2009) An embryonic stem cell chromatin
remodeling complex, esBAF, is essential for embryonic stem cell self-renewal
and pluripotency. Proc. Natl. Acad. Sci. USA 106, 5181–5186.
[98] Olave, I., Wang, W., Xue, Y., Kuo, A. and Crabtree, G.R. (2002) Identiﬁcation of
a polymorphic, neuron-speciﬁc chromatin remodeling complex. Genes Dev.
16, 2509–2517.
[99] Hassan, A.H., Prochasson, P., Neely, K.E., Galasinski, S.C., Chandy, M., Carrozza,
M.J. and Workman, J.L. (2002) Function and selectivity of bromodomains in
anchoring chromatin-modifying complexes to promoter nucleosomes. Cell
111, 369–379.[100] Li, Z.Y., Yang, J., Gao, X., Lu, J.Y., Zhang, Y., Wang, K., Cheng, M.B., Wu, N.H.,
Zhang, Y., Wu, Z. and Shen, Y.F. (2007) Sequential recruitment of PCAF and
BRG1 contributes to myogenin activation in 12-O-tetradecanoylphorbol-13-
acetate-induced early differentiation of rhabdomyosarcoma-derived cells. J.
Biol. Chem. 282, 18872–18878.
[101] Armstrong, J.A., Bieker, J.J. and Emerson, B.M. (1998) A SWI/SNF-related
chromatin remodeling complex, E-RC1, is required for tissue-speciﬁc
transcriptional regulation by EKLF in vitro. Cell 95, 93–104.
[102] Fryer, C.J. and Archer, T.K. (1998) Chromatin remodelling by the
glucocorticoid receptor requires the BRG1 complex. Nature 393, 88–91.
[103] DiRenzo, J., Shang, Y., Phelan, M., Sif, S., Myers, M., Kingston, R. and Brown, M.
(2000) BRG-1 is recruited to estrogen-responsive promoters and cooperates
with factors involved in histone acetylation. Mol. Cell. Biol. 20, 7541–7549.
[104] Kadam, S. and Emerson, B.M. (2003) Transcriptional speciﬁcity of human
SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol. Cell 11,
377–389.
[105] de la Serna, I.L., Ohkawa, Y. and Imbalzano, A.N. (2006) Chromatin
remodelling in mammalian differentiation: lessons from ATP-dependent
remodellers. Nat. Rev. Genet. 7, 461–473.
[106] Chiba, H., Muramatsu, M., Nomoto, A. and Kato, H. (1994) Two human
homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma
are transcriptional coactivators cooperating with the estrogen receptor and
the retinoic acid receptor. Nucl. Acids Res. 22, 1815–1820.
[107] Muchardt, C. and Yaniv, M. (1993) A human homologue of Saccharomyces
cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional
activation by the glucocorticoid receptor. EMBO J. 12, 4279–4290.
[108] Wallberg, A.E., Neely, K.E., Hassan, A.H., Gustafsson, J.A., Workman, J.L. and
Wright, A.P. (2000) Recruitment of the SWI–SNF chromatin remodeling
complex as a mechanism of gene activation by the glucocorticoid receptor
tau1 activation domain. Mol. Cell. Biol. 20, 2004–2013.
[109] Debril, M.B., Gelman, L., Fayard, E., Annicotte, J.S., Rocchi, S. and Auwerx, J.
(2004) Transcription factors and nuclear receptors interact with the SWI/SNF
complex through the BAF60c subunit. J. Biol. Chem. 279, 16677–16686.
[110] Rangwala, S.M. and Lazar, M.A. (2000) Transcriptional control of
adipogenesis. Ann. Rev. Nutr. 20, 535–559.
[111] Rosen, E.D. and Spiegelman, B.M. (2000) Molecular regulation of
adipogenesis. Ann. Rev. Cell Dev. Biol. 16, 145–171.
[112] Debril, M.B., Fajas, L., Renaud, J.P. and Auwerx, J. (2001) The pleiotropic
functions of peroxisome proliferator-activated receptor gamma. J. Mol. Med.
79, 30–47.
[113] Handschin, C. and Spiegelman, B.M. (2006) Peroxisome proliferator-activated
receptor gamma coactivator 1 coactivators, energy homeostasis, and
metabolism. Endocr. Rev. 27, 728–735.
[114] Tontonoz, P., Hu, E. and Spiegelman, B.M. (1994) Stimulation of adipogenesis
in ﬁbroblasts by PPARc2, a lipid-activated transcription factor. Cell 79, 1147–
1156.
[115] Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I. and Spiegelman, B.M. (1994)
mPPARgamma2: tissue-speciﬁc regulator of an adipocyte enhancer. Genes
Dev. 8, 1224–1234.
[116] Qi, C., Zhu, Y. and Reddy, J.K. (2000) Peroxisome proliferator-activated
receptors, coactivators, and downstream targets. Cell. Biochem. Biophys. 32,
187–204.
[117] Gurnell, M. (2003) PPARgamma and metabolism: insights from the study of
human genetic variants. Clin. Endocrinol. (Oxf.) 59, 267–277.
[118] Meirhaeghe, A. and Amouyel, P. (2004) Impact of genetic variation of
PPARgamma in humans. Mol. Genet. Metab. 83, 93–102.
[119] Farmer, S.R. (2006) Transcriptional control of adipocyte formation. Cell
Metab. 4, 263–273.
[120] Dahiya, A., Wong, S., Gonzalo, S., Gavin, M. and Dean, D.C. (2001) Linking the
Rb and polycomb pathways. Mol. Cell 8, 557–569.
[121] Salma, N., Xiao, H., Mueller, E. and Imbalzano, A.N. (2004) Temporal
recruitment of transcription factors and SWI/SNF chromatin-remodeling
enzymes during adipogenic induction of the Peroxisome Proliferator-
Activated Receptor-gamma nuclear hormone receptor. Mol. Cell. Biol. 24,
4651–4663.
[122] Musri, M.M., Gomis, R. and Párrizas, M. (2007) Chromatin and chromatin-
modifying proteins in adipogenesis. Biochem. Cell. Biol. 85, 397–410.
[123] Powell, E., Kuhn, P. and Xu, W. (2007) Nuclear receptor cofactors in
PPARgamma-mediated adipogenesis and adipocyte energy metabolism.
PPAR Res. 2007, 53843–53854.
[124] Tamori, Y., Masugi, J., Nishino, N. and Kasuga, M. (2002) Role of peroxisome
proliferator-activated receptor-gamma in maintenance of the characteristics
of mature 3T3-L1 adipocytes. Diabetes 51, 2045–2055.
[125] Wang, Z., Qi, C., Krones, A., Woodring, P., Zhu, X., Reddy, J.K., Evans, R.M.,
Rosenfeld, M.G. and Hunter, T. (2006) Critical roles of the p160
transcriptional coactivators p/CIP and SRC-1 in energy balance. Cell Metab.
3, 111–122.
[126] Louet, J.F. and O’Malley, B.W. (2007) Coregulators in adipogenesis: what
could we learn from the SRC (p160) coactivator family? Cell Cycle 6, 2448–
2452.
[127] Villarroya, F., Iglesias, R. and Giralt, M. (2007) PPARs in the control of
uncoupling proteins gene expression. PPAR Res. 2007, 74364–74376.
[128] Kontani, Y., Wang, Y., Kimura, K., Inokuma, K.I., Saito, M., Suzuki-Miura, T.,
Wang, Z., Sato, Y., Mori, N. and Yamashita, H. (2005) UCP1 deﬁciency
increases susceptibility to diet-induced obesity with age. Aging Cell 4, 147–
155.
3268 G.V. Denis et al. / FEBS Letters 584 (2010) 3260–3268[129] Salopuro, T., Lindström, J., Eriksson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-
Parikka, P., Keinänen-Kiukaanniemi, S., Tuomilehto, J., Laakso, M. and
Uusitupa, M. (2004) Common variants in beta2- and beta3-adrenergic
receptor genes and uncoupling protein 1 as predictors of the risk for type
2 diabetes and body weight changes. The Finnish Diabetes Prevention Study.
Clin. Genet. 66, 365–367.
[130] Malik, S., Wallberg, A.E., Kang, Y.K. and Roeder, R.G. (2002) TRAP/SMCC/
mediator-dependent transcriptional activation from DNA and chromatin
templates by orphan nuclear receptor hepatocyte nuclear factor 4. Mol. Cell.
Biol. 22, 5626–5637.
[131] Wallberg, A.E., Yamamura, S., Malik, S., Spiegelman, B.M. and Roeder, R.G.
(2003) Coordination of p300-mediated chromatin remodeling and
TRAP/mediator function through coactivator PGC-1alpha. Mol. Cell 12,
1137–1149.
[132] Chen, W., Yang, Q. and Roeder, R.G. (2009) Dynamic interactions and
cooperative functions of PGC-1alpha and MED1 in TRalpha-mediated
activation of the brown-fat-speciﬁc UCP-1 gene. Mol. Cell 35, 755–768.
[133] Myers, L.C., Gustafsson, C.M., Bushnell, D.A., Lui, M., Erdjument-Bromage, H.,
Tempst, P. and Kornberg, R.D. (1998) The Med proteins of yeast and their
function through the RNA polymerase II carboxy-terminal domain. Genes
Dev. 12, 45–54.
[134] Jiang, Y.W., Veschambre, P., Erdjument-Bromage, H., Tempst, P., Conaway,
J.W., Conaway, R.C. and Kornberg, R.D. (1998) Mammalian mediator of
transcriptional regulation and its possible role as an end-point of signal
transduction pathways. Proc. Natl. Acad. Sci. USA 95, 8538–8543.
[135] Kuras, L., Borggrefe, T. and Kornberg, R.D. (2003) Association of the Mediator
complex with enhancers of active genes. Proc. Natl. Acad. Sci. USA 100,
13887–13891.
[136] Nofsinger, R.R., Li, P., Hong, S.H., Jonker, J.W., Barish, G.D., Ying, H., Cheng, S.Y.,
Leblanc, M., Xu, W., Pei, L., Kang, Y.J., Nelson, M., Downes, M., Yu, R.T., Olefsky,
J.M., Lee, H. and Evans, R.M. (2008) SMRT repression of nuclear receptors
controls the adipogenic set point and metabolic homeostasis. Proc. Natl.
Acad. Sci. USA 105, 20021–20026.
[137] Foryst-Ludwig, A., Clemenz, M., Hohmann, S., Hartge, M., Sprang, C., Frost, N.,
Krikov, M., Bhanot, S., Barros, R., Morani, A., Gustafsson, J.A., Unger, T. and
Kintscher, U. (2008) Metabolic actions of estrogen receptor beta (ERbeta) are
mediated by a negative crosstalk with PPARgamma. PLoS Genet. 4,
e1000108–e1000124.
[138] Samarasinghe, S.P., Sutanto, M.M., Danos, A.M., Johnson, D.N., Brady, M.J. and
Cohen, R.N. (2009) Altering PPARgamma ligand selectivity impairs
adipogenesis by thiazolidinediones but not hormonal inducers. Obesity
(Silver Spring) 17, 965–972.
[139] Ge, K., Guermah, M., Yuan, C.X., Ito, M., Wallberg, A.E., Spiegelman, B.M. and
Roeder, R.G. (2002) Transcription coactivator TRAP220 is required for PPAR
gamma 2-stimulated adipogenesis. Nature 417, 563–567.
[140] Rando, O.J., Zhao, K., Janmey, P. and Crabtree, G.R. (2002)
Phosphatidylinositol-dependent actin ﬁlament binding by the SWI/SNF-like
BAF chromatin remodeling complex. Proc. Natl. Acad. Sci. USA 99, 2824–
2829.
[141] Serra, C., Palacios, D., Mozzetta, C., Forcales, S.V., Morantte, I., Ripani, M.,
Jones, R., Du, K., Jhala, U.S., Simone, C. and Puri, P.L. (2007) Functional
interdependence at the chromatin level between the MKK6/p38 and
IGF1/PI3K/AKT pathways during muscle differentiation. Mol. Cell 28, 200–
213.[142] Dunn, K.L., Espino, P.S., Drobic, B., He, S. and Davie, J.R. (2005) The Ras-MAPK
signal transduction pathway, cancer and chromatin remodeling. Biochem.
Cell. Biol. 83, 1–14.
[143] Medzhitov, R. and Horng, T. (2009) Transcriptional control of the
inﬂammatory response. Nat. Rev. Immunol. 9, 692–703.
[144] Jagannathan, M., Hasturk, H., Liang, Y., Shin, H., Hetzel, J.T., Kantarci, A.,
Rubin, D., McDonnell, M.E., Van Dyke, T.E., Ganley-Leal, L.M. and Nikolajczyk,
B.S. (2009) TLR crosstalk speciﬁcally regulates cytokine production by B cells
from chronic inﬂammatory disease patients. J. Immunol. 183, 7461–7470.
[145] Zhang, B., Chambers, K.J., Faller, D.V. and Wang, S. (2007) Reprogramming of
the SWI/SNF complex for co-activation or co-repression in prohibitin-
mediated estrogen receptor regulation. Oncogene 26, 7153–7157.
[146] Fajas, L., Landsberg, R.L., Huss-Garcia, Y., Sardet, C., Lees, J.A. and Auwerx, J.
(2002) E2Fs regulate adipocyte differentiation. Dev. Cell 3, 39–49.
[147] Mellor, J. (2005) The dynamics of chromatin remodeling at promoters. Mol.
Cell 19, 147–157.
[148] Schnitzler, G., Sif, S. and Kingston, R.E. (1998) Human SWI/SNF interconverts
a nucleosome between its base state and a stable remodeled state. Cell 94,
17–27.
[149] Pospisilik, J.A., Schramek, D., Schnidar, H., Cronin, S.J., Nehme, N.T., Zhang, X.,
Knauf, C., Cani, P.D., Aumayr, K., Todoric, J., Bayer, M., Haschemi, A.,
Puviindran, V., Tar, K., Orthofer, M., Neely, G.G., Dietzl, G., Manoukian, A.,
Funovics, M., Prager, G., Wagner, O., Ferrandon, D., Aberger, F., Hui, C.C.,
Esterbauer, H. and Penninger, J.M. (2010) Drosophila genome-wide obesity
screen reveals hedgehog as a determinant of brown versus white adipose cell
fate. Cell 140, 148–160.
[150] Tseng, Y.H. and He, T.C. (2007) Bone morphogenetic proteins and adipocyte
differentiation. Cell Sci. Rev. 3, 342–360.
[151] Graff, J.M. (1997) Embryonic patterning: to BMP or not to BMP, that is the
question. Cell 89, 171–174.
[152] Seale, P., Kajimura, S., Yang, W., Chin, S., Rohas, L.M., Uldry, M., Tavernier, G.,
Langin, D. and Spiegelman, B.M. (2007) Transcriptional control of brown fat
determination by PRDM16. Cell Metab. 6, 38–54.
[153] Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M. and Spiegelman, B.M.
(1998) A cold-inducible coactivator of nuclear receptors linked to adaptive
thermogenesis. Cell 92, 829–839.
[154] Tseng, Y.H., Kokkotou, E., Schulz, T.J., Huang, T.L., Winnay, J.N., Taniguchi,
C.M., Tran, T.T., Suzuki, R., Espinoza, D.O., Yamamoto, Y., Ahrens, M.J., Dudley,
A.T., Norris, A.W., Kulkarni, R.N. and Kahn, C.R. (2008) New role of bone
morphogenetic protein 7 in brown adipogenesis and energy expenditure.
Nature 454, 1000–1004.
[155] You, J., Denis, G.V., Srinivasan, V., Ballestas Jr., M.E., Harrington, W.J., Kaye,
K.M. and Howley, P.M. (2006) Kaposi’s Sarcoma-associated herpesvirus
latency-associated nuclear antigen interacts with bromodomain protein
Brd4 on host mitotic chromosomes. J. Virol. 80, 8909–8919.
[156] Kyle, U.G. and Pichard, C. (2006) The Dutch Famine of 1944–1945: a
pathophysiological model of long-term consequences of wasting disease.
Curr. Opin. Clin. Nutr. Metab. Care 9, 388–394.
[157] Bocock, P.N. and Aagaard-Tillery, K.M. (2009) Animal models of epigenetic
inheritance. Semin. Reprod. Med. 27, 369–379.
[158] Ruderman, N.B., Schneider, S.H. and Berchtold, P. (1981) The ”metabolically-
obese,” normal-weight individual. Am. J. Clin. Nutr. 34, 1617–1621.
[159] Shoelson, S.E., Lee, J. and Goldﬁne, A.B. (2006) Inﬂammation and insulin
resistance. J. Clin. Invest. 116, 1793–1801.
